## Amendment Tool

v1.6 06 December 2021

For office use

QC: No

Short project title*:	MAPS-2							
IRAS project ID* (or REC reference if no IRAS project ID is available):	290474							
Sponsor amendment reference number*:								
Sponsor amendment date* (enter as DD/MM/YY):	29 June 2022							
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	that are struggling to failed bedside assess bedside assessment known well." (in relati to confuse research sentence was redun 2) University Hospitat the study. 3) There has been a 4) Friarage Hospitat Hospitat (South Teess (No PIs). Stepping H recruiting site: PI: Dr. A protocol amendme	riteria in the protocol has been slightly amended as per feedback from si to recruit. Patients must now have an NIHSS 10≥, OR NIHSS 6≥ and a sessment of swallowing (instead of having an NIHSS 10≥ AND a failed ent of swallowing). The sentence "unless this is more than 12 h from la lation to the recruitment time window) has been removed, as this was fo ch staff. The CI and TSC agreed the above protocol changes and that th undant. bital Coventry and Royal United Hospital Bath have withdrawn from settir in a change in PI at University Hospital of North Tees. al (South Tees Hospitals NHS Foundation Trust) and Redcar Primary Ca ses Hospitals NHS Foundation Trust) have been added as repatriation s g Hill Hospital (Stockport NHS Foundation Trust) has been added as a ne Dr. Appukuttan Suman. ment table has been added to the final page of the protocol, which will mmarise all protocol changes going forward in the trial.						
				Specific stu	udy			
Project type (select):		Research tissue bank						
		Research database						
Has the study been reviewed by a UKECA-recognised Res Committee (REC) prior to this amendment?:	search Ethics	Ye	es	No				
What type of UKECA-recognised Research Ethics Commit is applicable? (select):								
Is all or part of this amendment being resubmitted to the Re Committee (REC) as a <b>modified amendment</b> (i.e. a substa		Y	es		Defence (MoDREC			
					No			
Committee (REC) as a modified amendment (i.e. a substa	antial	England Yes	es Wales No		No			
Committee (REC) as a <b>modified amendment</b> (i.e. a substrained ment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?: Was the study a clinical trial of an investigational medicinal	antial ) that reviewed	England Yes	Wales	Scotland	No Northern Irelar			
Committee (REC) as a <b>modified amendment</b> (i.e. a substrained ment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?:	antial ) that reviewed	England Yes	Wales No	Scotland	No Northern Irelar No			
Committee (REC) as a <b>modified amendment</b> (i.e. a substrained ment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?: Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	ontial ) that reviewed product (CTIMP) roduct (CTIMP)	England Yes Ye	Wales No	Scotland	No Northern Irelan No			
Committee (REC) as a <b>modified amendment</b> (i.e. a substa amendment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?: Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?: EudraCT number*: Was this clinical trial of an investigational medicinal pr processed under the CTIMP combined review service	ontial ) that reviewed product (CTIMP) roduct (CTIMP)	England Yes Ye	Wales No es	Scotland	No Northern Irelar No No No No			
Committee (REC) as a <b>modified amendment</b> (i.e. a substa amendment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?: Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?: EudraCT number*: Was this clinical trial of an investigational medicinal pr processed under the CTIMP combined review service as the Combined Ways of Working (CWoW) pilot)?:	antial ) that reviewed product (CTIMP) roduct (CTIMP) e (formerly known	England Yes Ye 2021-003853-4	Wales No es 0 Yes	Scotland No	No Northern Irelar No No No No			
Committee (REC) as a <b>modified amendment</b> (i.e. a substa amendment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?: Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?: EudraCT number*: Was this clinical trial of an investigational medicinal pr processed under the CTIMP combined review service as the Combined Ways of Working (CWoW) pilot)?: Did the study receive Pharmacy Assurance?: Was the study a clinical investigation or other study of a me	antial ) that reviewed product (CTIMP) coduct (CTIMP) e (formerly known edical device OR stances, therefore	England Yes 2021-003853-4	Wales No es 0 Yes Yes	Scotland No	No Northern Irelar No			
Committee (REC) as a <b>modified amendment</b> (i.e. a substa amendment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?: Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?: EudraCT number*: Was this clinical trial of an investigational medicinal pr processed under the CTIMP combined review service as the Combined Ways of Working (CWoW) pilot)?: Did the study receive Pharmacy Assurance?: Was the study a clinical investigation or other study of a me does the amendment make it one?: Did the study involve the administration of radioactive subs	antial ) that reviewed product (CTIMP) coduct (CTIMP) e (formerly known edical device OR stances, therefore ce this?: ising radiation	England Yes Yu 2021-003853-4	Wales No es 0 Yes Yes	Scotland No	No No No No No			
Committee (REC) as a <b>modified amendment</b> (i.e. a substa amendment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?: Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?: EudraCT number*: Was this clinical trial of an investigational medicinal pr processed under the CTIMP combined review service as the Combined Ways of Working (CWoW) pilot)?: Did the study receive Pharmacy Assurance?: Was the study a clinical investigation or other study of a me does the amendment make it one?: Did the study involve the administration of radioactive subs requiring ARSAC review, OR does the amendment introduc Did the study involve the use of research exposures to ioni (not involving the administration of radioactive substances)	antial ) that reviewed product (CTIMP) coduct (CTIMP) e (formerly known edical device OR stances, therefore ce this?: ising radiation OR does the n Assurance	England Yes Yu 2021-003853-4	Wales No es O Yes es es	Scotland No	No N			
Committee (REC) as a <b>modified amendment</b> (i.e. a substa amendment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?: Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?: EudraCT number*: Was this clinical trial of an investigational medicinal pr processed under the CTIMP combined review service as the Combined Ways of Working (CWoW) pilot)?: Did the study receive Pharmacy Assurance?: Was the study a clinical investigation or other study of a me does the amendment make it one?: Did the study involve the administration of radioactive subs requiring ARSAC review, OR does the amendment introduu Did the study involve the use of research exposures to ioni (not involving the administration of radioactive substances) amendment introduce this?: Did the study have Radiation Assurance OR is Radiation	antial ) that reviewed product (CTIMP) coduct (CTIMP) e (formerly known edical device OR stances, therefore ce this?: ising radiation OR does the n Assurance nt?:	England Yes Yu 2021-003853-4	Wales No es 0 Yes es es es	Scotland No	No N			
Committee (REC) as a <b>modified amendment</b> (i.e. a substa amendment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?: Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?: EudraCT number*: Was this clinical trial of an investigational medicinal pr processed under the CTIMP combined review service as the Combined Ways of Working (CWOW) pilot)?: Did the study receive Pharmacy Assurance?: Was the study a clinical investigation or other study of a me does the amendment make it one?: Did the study involve the administration of radioactive subs requiring ARSAC review, OR does the amendment introdu Did the study involve the use of research exposures to ioni (not involving the administration of radioactive substances) amendment introduce this?: Did the study have Radiation Assurance OR is Radiation being sought for the first time because of this amendment Did the study involve adults lacking capacity OR does the amendment	antial ) that reviewed product (CTIMP) coduct (CTIMP) e (formerly known edical device OR stances, therefore ce this?: sing radiation OR does the n Assurance nt?: amendment tion outside the	England Yes Yu 2021-003853-4 Yu Yu Yu Yu	Wales No es 0 Yes es es es yes	Scotland No	No N			
Committee (REC) as a <b>modified amendment</b> (i.e. a substa amendment previously given an unfavourable opinion)? Where is the NHS/HSC Research Ethics Committee (REC) the study based?: Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?: EudraCT number*: Was this clinical trial of an investigational medicinal pr processed under the CTIMP combined review service as the Combined Ways of Working (CWoW) pilot)?: Did the study receive Pharmacy Assurance?: Was the study a clinical investigation or other study of a me does the amendment make it one?: Did the study involve the administration of radioactive subs requiring ARSAC review, OR does the amendment introdu Did the study involve the use of research exposures to ioni (not involving the administration of radioactive substances) amendment introduce this?: Did the study involve adults lacking capacity OR does the a introduce this?:	antial ) that reviewed product (CTIMP) coduct (CTIMP) e (formerly known edical device OR stances, therefore ce this?: ising radiation OR does the n Assurance nt?: amendment tion outside the i introduce this?: e in custody or	England Yes Yu 2021-003853-4 Yu Yu Yu Yu	Wales No PS Ves Ves es S Ves Ves S S S S S S S S S S S S S S S S S S S	Scotland No	Northern Irelan No			

Did the study involve NHS/HSC organisations prior to this amendment?:	Y	es	No			
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Y	'es	No			
	England Wales Scotland		Scotland	Northern Ireland		
Lead nation for the study:	Yes	No	No	No		
Which nations had participating NHS/HSC organisations prior to this amendment?	Yes	Yes	Yes	Yes		
Which nations will have participating NHS/HSC organisations after this amendment?	Yes	Yes	Yes	Yes		

## Section 2: Summary of change(s)

Г

What do you want to update?:	Project information
	New site/PI only

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

	Change 1		
Area of change (select)*:	Study Design		
Specific change (select - only available when area of change is selected first)*:	Inclusion/exclusion criteria - Minor change unlikely to affe	ct safety or scientif	ic value of study
Further information (free text - note that this field will adapt to the amount of text entered):	The inclusion criteria has been amended to include patien >=6 AND a failed bedside assessment of swallowing. Par both to be eligibile for trial entry. Changing from AND to C not affect the scientific validity of the trial, as both NIHSS predict pneumonia and mortality. Therefore the frequency not be affected by the change in patietns with stroke. As NIHSS>=6 to dysphagia. While dysphagia itself is suffifici present with dysphagia and non-stroke conditions. Addin these. Additionally, The sentence in the inclusion criteria a from last known well." (in relation to the recruitment time of and TSC agreed this was not required and risked confusi	ients are no longer PR for dysphagia ar >=10 and dysphagi y of outcomes (dea a further safeguard ent in definite strok g a minimum NIHS #2 "unless this is window) has been r	required to have nd NIHSS>=10 will a independently th, pneumonia) will I we added es, some patients S will exclude more than 12 h removed, as the CI
Applicability:	England Wales	Scotland	Northern Ireland

Applicability:	England	Wales	Scotland	Northern Ireland	
Where are the participating NHS/HSC organisations located that will be affected by this change?*:	Yes	Yes	Yes	Yes	
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):			Some		
			Remove all c	hanges below	

Remove all changes below

Change 2										
Area of change (select)*:	Participating Organisa	ations								
Specific change (select - only available when area of change is selected first)*:	Early closure or withdrawal of research sites									
Further information (free text - note that this field will adapt to the amount of text entered):		The following two recruiting sites are no longer able to participate in MAPS-2 and have thus withdrawn from study set-up: University Hospital Coventry and Royal United Hospital Bath.								
Applicability:		England	Wales	Scotland	Northern Ireland					
Where are the participating NHS/HSC organisations locate by this change?*:	ed that will be affected	Yes	Yes Yes Yes Yes							
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the catego change):					Some					
				Remove all changes below						
enangoj.			Remove all	changes belo						

	Change 3
Area of change (select)*:	Researchers
Specific change (select - only available when area of change is selected first)*:	PI - New PI, or temporary arrangements to cover the absence of a PI

Further information (free text - note that this field will adapt to the amount of text entered):

change):

Dr. Sarah Whitehouse has replaced Dr. Ijaz Anwar at University Hospital of North Tees (North Tees and Hartlepool Hospitals NHS Foundation Trust).

Remove all changes below

Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*:	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	A	JI	Sc	ome
			Remove all c	hanges below

	Change 4										
Area of change (select)*:	Participating Organisa	Participating Organisations									
Specific change (select - only available when area of change is selected first)*:	Addition of sites undertaking the same activities as existing sites										
Further information (free text - note that this field will adapt to the amount of text entered):	Two new repatriation Hospital (both South that repatriation sites Foundation Trust) ha	Tees Hospitals NH do not require Pis	S Foundation True in MAPS-2. Stepp	st). It has already b ing Hill Hospital (S	been confirmed tockport NHS						
Applicability:	·	England	Wales	Scotland	Northern Ireland						
Where are the participating NHS/HSC organisations locate by this change?*:	ed that will be affected	Yes	No	No	No						
Will all participating NHS/HSC organisations be affected b some? (please note that this answer may affect the category		A	JI	So	ome						

Change 5 Area of change (select)\*: Study Documents Specific change (select - only available when area of Protocol - Non-substantial changes (e.g. not affecting safety or the scientific value of the trial) change is selected first)\*: Further information (free text - note that this field will adapt to the amount of text entered): A protocol amendment table has been inserted into the final page of the protocol. This table will document and summarise all protocol changes going forward. Applicability: Wales Northern Ireland England Scotland Where are the participating NHS/HSC organisations located that will be affected Yes No No No by this change?\*: Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the All Some change): Add another change

Declaration by the Sponsor or authorised	delegate				
<ul> <li>I confirm that the Sponsor takes responsib</li> <li>I confirm that I have been formally authoris</li> </ul>	ility for the completed amendment tool sed by the Sponsor to complete the amendment tool on their behalf				
Name [first name and surname]*:	Angela Shone				
Email address*:	sponsor@nottingham.ac.uk				
.ock for submission					
	railable when all mandatory (*) fields have been completed. When the button is available, clicking it will d amendment tool which must be included in the amendment submission. Please ensure that the amendment				

Section	4:	Review	bodies	for	the	amendment
0000000		110 110 10	Donica	101	uic	amenament

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

								F	Review	bodie	s								
	UK wide:				England and Wales: Scotland:				Northern Ireland:										
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	SAAMH	HRA and HCRW Approval	REC (AWIA)	РВРР	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	Category
Change 1:		ΟΣ	ΟΣ	A		⊃ (Y)	Ľ	Ó	I	エ (Y)	Ľ		0	Z (Y)	I	I	Ē	Z (Y)	A
Change 2:						(Y)				(Y)				(Y)				(Y)	А
Change 3:						(Y)				(Y)				(Y)				(Y)	А
Change 4:						(Y)				(Y)				(Y)				(Y)	New site
Change 5:						(Y)				(Y)				Ν				Ν	В
Overall reviews for the amend	ment:																		
Full review:						Ν				Ν				Ν				Ν	
Notification only:						Y				Υ				Υ				Y	
Overall amendment type:	No	n-sub	stantia	l, no s	tudy-w	vide re	view r	equire	d	•		•	•		•	•	•	•	
Overall Category:	A																		